Re: Robert J. Motzer, Paul Russo, Naomi Haas, et al. Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients with Localized or Locally Advanced Renal Cell Carcinoma: Final Overall Survival Analysis of the Phase 3 PROTECT Trial. Eur Urol 2021;79:334–8

Phase 3 ◽

Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma: Final Overall Survival Analysis of the Phase 3 PROTECT Trial

European Urology ◽

10.1016/j.eururo.2020.12.029 ◽

2021 ◽

Vol 79 (3) ◽

pp. 334-338

Author(s):

Robert J. Motzer ◽

Paul Russo ◽

Naomi Haas ◽

Christian Doehn ◽

Frede Donskov ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Overall Survival ◽

Survival Analysis ◽

Cell Carcinoma ◽

Renal Cell ◽

Locally Advanced ◽

Phase 3 ◽

Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial

The Lancet Oncology ◽

10.1016/s1470-2045(13)70093-7 ◽

2013 ◽

Vol 14 (6) ◽

pp. 552-562 ◽

Cited By ~ 455

Author(s):

Robert J Motzer ◽

Bernard Escudier ◽

Piotr Tomczak ◽

Thomas E Hutson ◽

M Dror Michaelson ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Overall Survival ◽

Survival Analysis ◽

Cell Carcinoma ◽

Renal Cell ◽

Line Treatment ◽

Second Line ◽

Phase 3 ◽

Predicting Disease Recurrence, Early Progression, and Overall Survival Following Surgical Resection for High-risk Localized and Locally Advanced Renal Cell Carcinoma

European Urology ◽

10.1016/j.eururo.2021.02.025 ◽

2021 ◽

Author(s):

Andres F. Correa ◽

Opeyemi A. Jegede ◽

Naomi B. Haas ◽

Keith T. Flaherty ◽

Michael R. Pins ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Overall Survival ◽

High Risk ◽

Cell Carcinoma ◽

Surgical Resection ◽

Renal Cell ◽

Locally Advanced ◽

Disease Recurrence ◽

Early Progression

Overall survival analysis from a randomized phase II study of axitinib with or without dose titration for first-line metastatic renal cell carcinoma.

Journal of Clinical Oncology ◽

10.1200/jco.2015.33.15_suppl.4545 ◽

2015 ◽

Vol 33 (15_suppl) ◽

pp. 4545-4545 ◽

Cited By ~ 1

Author(s):

Brian I. Rini ◽

Yoshihiko Tomita ◽

Bohuslav Melichar ◽

Takeshi Ueda ◽

Viktor Grünwald ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Overall Survival ◽

Survival Analysis ◽

Cell Carcinoma ◽

Renal Cell ◽

Phase Ii Study ◽

Dose Titration ◽

First Line ◽

Randomized Phase Ii ◽

Overall survival results from the phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma (METEOR)

European Journal of Cancer ◽

10.1016/s0959-8049(17)30678-0 ◽

2017 ◽

Vol 72 ◽

pp. S187-S188

Author(s):

M. Schmidinger ◽

R.J. Motzer ◽

T. Powles ◽

B. Escudier ◽

N.M. Tannir ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Overall Survival ◽

Cell Carcinoma ◽

Renal Cell ◽

Phase 3

Overall survival (OS) in METEOR, a randomized phase 3 trial of cabozantinib (Cabo) versus everolimus (Eve) in patients (pts) with advanced renal cell carcinoma (RCC).

Journal of Clinical Oncology ◽

10.1200/jco.2016.34.15_suppl.4506 ◽

2016 ◽

Vol 34 (15_suppl) ◽

pp. 4506-4506 ◽

Cited By ~ 1

Author(s):

Toni K. Choueiri ◽

Thomas Powles ◽

Bernard J. Escudier ◽

Nizar M. Tannir ◽

Paul Mainwaring ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Overall Survival ◽

Cell Carcinoma ◽

Renal Cell ◽

Phase 3

Overall Survival Analysis From a Randomized Phase II Study of Axitinib With or Without Dose Titration in First-Line Metastatic Renal Cell Carcinoma

Clinical Genitourinary Cancer ◽

10.1016/j.clgc.2016.04.005 ◽

2016 ◽

Vol 14 (6) ◽

pp. 499-503 ◽

Cited By ~ 31

Author(s):

Brian I. Rini ◽

Yoshihiko Tomita ◽

Bohuslav Melichar ◽

Takeshi Ueda ◽

Viktor Grünwald ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Overall Survival ◽

Survival Analysis ◽

Cell Carcinoma ◽

Renal Cell ◽

Phase Ii Study ◽

Dose Titration ◽

First Line ◽

Randomized Phase Ii ◽

Faculty Opinions recommendation of Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.13484037.14861147 ◽

2012 ◽

Author(s):

Thomas Powles

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Renal Cell ◽

Comparative Effectiveness ◽

Phase 3

TIVO-3: A Phase 3, Randomised, Open-Label Study Comparing Tivozanib to Sorafenib in Patients with Advanced Renal Cell Carcinoma

SSRN Electronic Journal ◽

10.2139/ssrn.3427299 ◽

2019 ◽

Author(s):

Brian Rini ◽

Sumanta K. Pal ◽

Bernard J. Escudier ◽

Michael B. Atkins ◽

Thomas E. Hutson ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Renal Cell ◽

Open Label ◽

Phase 3 ◽

Open Label Study ◽

Label Study

Re: Comparative Effectiveness of Axitinib versus Sorafenib in Advanced Renal Cell Carcinoma (AXIS): A Randomised Phase 3 Trial

The Journal of Urology ◽

10.1016/j.juro.2012.04.069 ◽

2012 ◽

Vol 188 (2) ◽

pp. 412-413

Author(s):

Samir S. Taneja

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Renal Cell ◽

Comparative Effectiveness ◽

Phase 3